FLT3 and acute myeloid leukemia: Trials of FLT3 inhibitors in FLT3-WT AML are ongoing, including a randomized phase III trial of chemotherapy +/− midostaurin (NCT03512197) and chemotherapy +/− quizartinib (NCT04107727), both in patients with newly-diagnosed FLT3-WT AML.